SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. (DJT) is actively trending as the community scrutinizes a recent presidential address, driving extensive discussion around potential policy shifts. Conversations are heavily focused on anticipated announcements regarding international affairs and economic conditions, along with ongoing political developments. Many investors highlight that the stock's movements are primarily fueled by political sentiment and narratives rather than traditional financial fundamentals.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending after reporting strong quarterly results and an exceptionally bullish outlook, primarily driven by surging demand for its high-bandwidth memory (HBM) in the AI sector. The community is actively discussing the company's sold-out HBM supply through 2026 and expanding gross margins, which many see as confirmation of a prolonged memory super cycle. Despite widespread optimism and numerous analyst upgrades, some investors remain cautious, referencing past market reactions to strong earnings.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is highly active amidst widespread anticipation of an Executive Order from President Trump, expected to reclassify marijuana to Schedule III. This potential policy shift is fueling significant community discussion, with many expecting a substantial market rally due to reduced tax burdens and increased institutional investment, although some debate whether it could be a "sell the news" event.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending due to a wave of analyst downgrades expressing concerns over its branded checkout growth and competitive landscape, igniting a sharp debate among investors. Many view the market's negative reaction as a forced capitulation to accumulate shares, pointing to robust buybacks, strategic AI partnerships, and its new bank charter application as strong long-term catalysts. However, skeptics maintain concerns over management's direction and potential shifts in valuation as PayPal evolves deeper into financial services.

Sable Offshore Corp. engages in offshore oil and gas field operations. It focuses on developing the prolific Santa Ynez Unit in federal waters offshore California. The company was founded by James C. Flores on October 16, 2020 and is headquartered in Houston, TX.

Sable Offshore Corp.

Sable Offshore Corp. is trending upward after its Santa Ynez pipeline was designated an interstate facility, shifting regulatory oversight to federal authorities. This development is driving significant community discussion, with many investors viewing it as a crucial step to overcome state-level hurdles for oil production and potentially trigger a short squeeze.

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Galectin Therapeutics Inc

Galectin Therapeutics is trending with intense community anticipation for imminent FDA guidance on its lead drug candidate, Belapectin, targeting MASH cirrhosis. The drug's compelling safety and efficacy data for a high unmet need, coupled with the CEO's enthusiastic "WOW" comments, are fueling widespread speculation about a potential buyout or partnership and significant upside. Discussions highlight the drug's potential as a first-in-class treatment and the underlying value in a market with no approved therapies, despite ongoing short interest.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

The AdvisorShares Pure US Cannabis ETF (MSOS) is trending as the cannabis sector anticipates a significant federal reclassification of marijuana, widely expected to be enacted via an executive order. This potential move to Schedule III is a key talking point among investors, who foresee substantial benefits for U.S. multi-state operators through immediate tax relief and the unlocking of institutional investment.

Accenture is a global professional services company that helps the world’s businesses, governments and other organizations build their digital core, optimize their operations, accelerate revenue growth and enhance citizen services, creating tangible value at speed and scale. The firm combines technology and leadership in cloud, data and AI with industry experience, functional expertise and global delivery capability. Its services include Strategy & Consulting, Technology, Operations, Industry X, and Song. It operates through the following geographical segments: North America, EMEA, and Growth Markets. The company was founded in 1989 and is headquartered in Dublin, Ireland.

Accenture plc - Ordinary Shares - Class A

Accenture is trending following strong financial results that exceeded expectations and significant advancements in its AI strategy. The community is actively discussing its new partnerships with OpenAI and Anthropic, which are seen as pivotal for driving enterprise AI adoption and training thousands of professionals. This strategic focus aims to solidify Accenture's position as a leader in digital transformation amidst evolving market dynamics.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is a top trending stock as investors eagerly await its upcoming earnings report, widely seen as a crucial test for its "Win Now" turnaround strategy. The community is actively debating whether the athletic giant can overcome market challenges and tariff pressures, with recent analyst upgrades and competitive landscape shifts, including buzz around potential athlete endorsements, fueling a polarized outlook.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon Athletica is experiencing a significant surge as activist investor Elliott Management has disclosed a substantial stake, reportedly pushing for new leadership and strategic changes. The community is highly optimistic that a CEO transition, coupled with strong international growth and a recent share repurchase authorization, signals a major brand turnaround and a potential strong rebound for the stock. Many view this as a pivotal moment for LULU after a period of underperformance, expecting continued upward momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Exploring Imunon's Earnings Expectations

IMUNON, Inc. (IMNN) said on Wednesday its first patient has been dosed with the firm’s lead candidate, IMNN-001, as part of a late-stage trial evaluating the drug in the treatment of women with newly diagnosed advanced ovarian cancer.Shares of the company traded 4% higher in morning trade at the time of writing.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IMNN">IMUNON</a> jumped from ‘bearish’ to ‘neutral’ over the past 24 hours while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:625/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_30_at_9_43_26_AM_png_dc891d230b.webp" alt="IMNN's Sentiment Meter and Message Volume as of 10 a.m. ET on July 30, 2025 | Source: Stocktwits" width="625" height="61"><figcaption>IMNN's Sentiment Meter and Message Volume as of 10 a.m. ET on July 30, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the company is undervalued.<stembedurl>https://stocktwits.com/ConcernedCitizen23/message/623007565</stembedurl>The late-stage <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.imunon.com/news-releases/news-release-details/imunon-announces-first-patient-dosed-phase-3-ovation-3-study">study</a> is aimed at assessing the safety and efficacy of IMNN-001 plus standard of care neoadjuvant and adjuvant chemotherapy of Paclitaxel and Carboplatin compared to standard of care chemotherapy alone.The primary endpoint of the study is overall survival or lengthening the lifespan of patients.The study will also check secondary endpoints such as surgical response score, chemotherapy response score, clinical response, and time to second-line treatment.“We have great urgency around this program because patients do not have any other options besides the standard of care, which includes neoadjuvant and adjuvant chemotherapy and surgery,” CEO Stacy Lindborg said.According to IMUNON, epithelial ovarian cancer is the sixth deadliest malignancy among women in the U.S. There are approximately 20,000 new cases of ovarian cancer every year, and approximately 70% are diagnosed in advanced Stage III/IV, the company said.Earlier this month, IMUNON completed a reverse stock split of its issued and outstanding common stock at a ratio of 1:15 to meet the minimum bid price requirement for continued listing on the Nasdaq.IMNN stock is down by 43% this year and by about 84% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/humana-announces-upbeat-earnings-raised-guidance/choXGmPR5zr">Humana Stock Gains On Upbeat Earnings And Raised Guidance, Draws Retail Praise</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Imunon Doses First Patient With Experimental Cancer Drug In Late-Stage Trial: Retail Thinks Company Is Undervalued

The trial is evaluating IMNN-001 in the treatment of women with newly diagnosed advanced ovarian cancer. 

Equity

The trial is evaluating IMNN-001 in the treatment of women with newly diagnosed advanced ovarian cancer. 


Imunon hit its highest levels in nearly three years Tuesday, fueled by its announcement to present Phase 2 OVATION 2 study immune biomarker data at the European Society for Medical Oncology Gynaecological Cancers Congress 2025.The accepted abstract presents the results of IMNN-001, an IL-12 gene therapy developed from Imunon's TheraPlas platform, used in conjunction with neoadjuvant and adjuvant chemotherapy treatments for newly diagnosed, advanced ovarian cancer patients.Imunon shares surged 95.69% to close at $2.27 on May 27, before pulling back 23.35% in after-hours trading to $1.74.Premal H. Thaker, the chair of the Ovation 2 and 3 study, will deliver the presentation at the June 19–21 Vienna-based congress.The announcement follows recent news that new Ovation 2 data will also be featured in an oral presentation at the 2025 ASCO Annual Meeting and published in Gynecologic Oncology.&nbsp;These results showed meaningful increases in overall and progression-free survival for the IMNN-001 treatment group, with a median 13-month improvement in overall survival.CEO Stacy Lindborg called the data “remarkable” and said the growing interest from EU and Latin American researchers reinforces confidence in the company’s Phase 3 Ovation 3 trial and regulatory ambitions.&nbsp;The Phase 3 Ovation 3 trial, which recently initiated its first two sites, will evaluate IMNN-001 plus chemotherapy versus chemotherapy alone in patients with Stage IIIC or IV epithelial ovarian cancer.&nbsp;The primary endpoint is overall survival.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 2,554% surge in 24-hour message volume.One user commented that anyone worried about the after-hours drop should note that the stock behaved similarly last Friday, followed by a strong run the next day.&nbsp;<stembedurl>https://stocktwits.com/NFD2/message/615992363</stembedurl>Another user highlighted the possibility of an upcoming press release announcing a major partnership with a big pharmaceutical company to support funding and potential licensing or commercialization deals, citing CEO comments from recent weeks.<stembedurl>https://stocktwits.com/gourmetmacncheese/message/615991264</stembedurl>The stock has risen 116% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Imunon Jumps 96% On Phase 2 Immune Biomarker Data Reveal Ahead of ESMO Congress; Retail Expects ‘Major’ Partnership News Soon

The data highlights promising results for IMNN-001, an IL-12 gene therapy for advanced ovarian cancer, boosting investor optimism ahead of its Phase 3 trial.

Retail buzz around Imunon rose sharply Thursday after the clinical-stage biotech company said it will no longer pursue a previously planned public offering.&nbsp;Imunon formally requested to retract its Form S-1 registration with the SEC after initially registering the document on April 4.The biotech firm's shares rose 4.1% to $0.42 on Thursday and surged another 15.5% in after-hours trading to $0.48.The news follows a first-quarter (Q1) financial update, which showed that Imunon decreased its net loss from $4.9 million last year to $4.1 million.Imunon reported a per-share loss of $0.28, below the consensus estimate of $0.36.R&amp;D cost reductions totaling $1.1 million drove an 18% decrease in operating expenses, bringing the total to $4.1 million.&nbsp;The decline was driven by spending reductions on the Ovation 2 study, the PlaCCine DNA vaccine trial, and platform development activities.Employee-related costs&nbsp;increased, causing general and administrative expenses to rise slowly to $2.0 million from $1.7 million last year, although lower legal fees helped partially offset this increase.The operating activities required $2.8 million in cash, a reduction of more than half compared to the $5.9 million used in Q1 2024.As of quarter-end, Imunon maintained $2.9 million in cash reserves and projects that these funds will support operations until late Q2 2025.CEO Stacy Lindborg highlighted clinical advancements, including the Ovation 3 pivotal study and ongoing results from the Ovation 2 trial, which showed that the DNA-based immunotherapy IMNN-001 increased progression-free and overall survival rates among patients newly diagnosed with ovarian cancer.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 2,120% surge in 24-hour message volume.One user suggested the move implies management may have “a much better option for funding,” citing recent earnings call comments from the CEO about active financing and partnership discussions.&nbsp;<stembedurl>https://stocktwits.com/ItTakesItAll/message/615624018</stembedurl>Another user called the update “great news,” pointing to the company’s low float.<stembedurl>https://stocktwits.com/ItTakesItAll/message/615621205</stembedurl>The stock has declined 60.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Close up of scientist hand inoculating an agar plates with bacteria in microbiology lab | Image source: Getty Images

Retail Bulls Cheer Imunon’s Pullback From Public Offering, Citing ‘Much Better Funding Options’

Shares jumped 15.5% after hours, as retail traders pointed to “much better funding options” hinted at during the firm’s recent earnings call.

Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm is also engaged in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.

Imunon Inc

Up more than 2%

Up 0–2%

Flat to down 2%

Down more than 2%

The S&P 500 is modestly lower so far in December, putting the Santa Claus rally in question. The Santa Claus rally refers to the market’s tendency to rise in the final weeks of the year—what do you expect from December 16 through December 31?

What do you expect the S&amp;P 500’s total return to be in the second half of December?

Stocktwits

What do you expect the S&P 500’s total return to be in the second half of December?

Current Price	$3.87
Prev Close	$3.88
Open	$3.83
Dividend Yield	0.00%
50-Day Moving Average	$4.30
Beta	0.55
Avg. Volume	53,174.68
PE Ratio	-0.37

52-Week High	$41.22
52-Week Low	$3.56
Market Capitalization	$11.91M
EPS (Annual)	-$21.10
Price to Book	2.75
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

IMNN
Imunon Inc

Feed

News

Sentiment

Fundamentals

Info

Latest IMNN News

IMNNImunon Inc